BRAF and melanoma: In an independent experiment, encorafenib or binimetinib (MEK inhibitor) alone showed a rapid blockage of the MAPK pathway after 30 minutes in a preclinical model of melanoma, a tumor type with very good response to BRAF inhibitor single agent, as well as in BRAFV600E PMP cells (Supplementary Fig. S5B and S5C left).